These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9298697)

  • 1. The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection.
    Rider CC
    Glycoconj J; 1997 Aug; 14(5):639-42. PubMed ID: 9298697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro.
    Rider CC; Coombe DR; Harrop HA; Hounsell EF; Bauer C; Feeney J; Mulloy B; Mahmood N; Hay A; Parish CR
    Biochemistry; 1994 Jun; 33(22):6974-80. PubMed ID: 7911328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The V3 region of gp120 is responsible for anti-HIV-1 activity of heparin sulphate.
    Jagodzinski PP; Trzeciak WH
    Acta Biochim Pol; 1998; 45(3):799-804. PubMed ID: 9918507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro.
    Stone AL; Melton DJ; Lewis MS
    Glycoconj J; 1998 Jul; 15(7):697-712. PubMed ID: 9881776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4.
    Harrop HA; Rider CC
    Glycobiology; 1998 Feb; 8(2):131-7. PubMed ID: 9451022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding.
    Harrop HA; Coombe DR; Rider CC
    AIDS; 1994 Feb; 8(2):183-92. PubMed ID: 8043225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low anticoagulant heparin retains anti-HIV type 1 activity in vitro.
    Coombe DR; Harrop HA; Watton J; Mulloy B; Barrowcliffe TW; Rider CC
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1393-6. PubMed ID: 8573397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: a new strategy towards AIDS chemotherapy.
    Baba M; Schols D; Pauwels R; Nakashima H; De Clercq E
    J Acquir Immune Defic Syndr (1988); 1990; 3(5):493-9. PubMed ID: 1691288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
    Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
    Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HIV-1 activity and structure-activity-relationship study of a fucosylated glycosaminoglycan from an echinoderm by targeting the conserved CD4 induced epitope.
    Lian W; Wu M; Huang N; Gao N; Xiao C; Li Z; Zhang Z; Zheng Y; Peng W; Zhao J
    Biochim Biophys Acta; 2013 Oct; 1830(10):4681-91. PubMed ID: 23769857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV type 1 infection of CD4+ T cells depends critically on basic amino acid residues in the V3 domain of envelope glycoprotein 120.
    Okada T; Patterson BK; Otto PA; Gurney ME
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):803-11. PubMed ID: 7986586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HIV-1 infectivity by low molecular weight heparin. Results of in vitro studies and a pilot clinical trial in patients with advanced AIDS.
    Howell AL; Taylor TH; Miller JD; Groveman DS; Eccles EH; Zacharski LR
    Int J Clin Lab Res; 1996; 26(2):124-31. PubMed ID: 8856366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility to highly sulphated glycosaminoglycans of human immunodeficiency virus type 1 replication in peripheral blood lymphocytes and monocyte-derived macrophages cell cultures.
    Bartolini B; Di Caro A; Cavallaro RA; Liverani L; Mascellani G; La Rosa G; Marianelli C; Muscillo M; Benedetto A; Cellai L
    Antiviral Res; 2003 Apr; 58(2):139-47. PubMed ID: 12742574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds.
    Meylan PR; Kornbluth RS; Zbinden I; Richman DD
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2910-6. PubMed ID: 7695283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes.
    Naarding MA; Baan E; Pollakis G; Paxton WA
    Retrovirology; 2007 Jan; 4():6. PubMed ID: 17263871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
    Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C
    Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HIV type 1 properties of chemically modified heparins with diminished anticoagulant activity.
    Lopalco L; Ciccomascolo F; Lanza P; Zoppetti G; Caramazza I; Leoni F; Beretta A; Siccardi AG
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):787-93. PubMed ID: 7986584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
    J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nef stimulates human immunodeficiency virus type 1 replication in primary T cells by enhancing virion-associated gp120 levels: coreceptor-dependent requirement for Nef in viral replication.
    Lundquist CA; Zhou J; Aiken C
    J Virol; 2004 Jun; 78(12):6287-96. PubMed ID: 15163722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
    Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
    Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.